PT  - JOURNAL ARTICLE
AU  - Meghan C. Ferrall-Fairbanks
AU  - Nicholas Chakiryan
AU  - Boris I. Chobrutskiy
AU  - Youngchul Kim
AU  - Jamie K. Teer
AU  - Anders Berglund
AU  - James Mulé
AU  - Michelle Fournier
AU  - Erin Siegel
AU  - Shayan Falasiri
AU  - Juan F. Arturo
AU  - Esther N. Katende
AU  - George Blanck
AU  - Brandon J. Manley
AU  - Philipp M. Altrock
TI  - Quantifying T- and B-cell immune receptor distribution diversity to uncover their clinical relevance in clear cell renal cell carcinoma
AID  - 10.1101/2021.06.15.21258987
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.15.21258987
4099  - http://medrxiv.org/content/early/2021/06/23/2021.06.15.21258987.short
4100  - http://medrxiv.org/content/early/2021/06/23/2021.06.15.21258987.full
AB  - Immune-modulating systemic therapies are often used to treat metastatic clear cell renal cell carcinoma (ccRCC). Used alone, sequence-based biomarkers neither accurately capture patient dynamics nor the tumor-immune microenvironment. To better understand the tumor ecology of this immune microenvironment, we used complementarity determining region-3 (CDR3) sequence recovery counts of the tumor infiltrating lymphocytes, and quantified tumor infiltration by sequences recovered from patient tumors by applying a generalized diversity index (GDI) to CDR3 sequence distributions across two distinct ccRCC cohorts. GDI can be understood as a curve over a continuum of diversity scales and allows sensitive characterization of distributions to capture richness, evenness, and subsampling uncertainty, along with other important metrics. For example, richness quantifies the total unique sequence count, while evenness quantifies similarities across sequence frequencies. We observed significant differences in receptor sequence diversity across gender and race. Further, our analysis revealed that patients with larger and more clinically aggressive tumors had increased richness of recovered tumoral CDR3 sequences, specifically in those from T-cell receptor alpha and B-cell immunoglobulin lambda light chain. We identified a novel and robust measure of distribution evenness, using GDI’s inflection point (IP). High IP values associated with improved overall survival, suggesting that normal-like sequence distributions lead to better outcomes. Our results propose a new quantitative tool that can be used to better characterize patient-level differences related to immune cell infiltration and, can be used to identify unique characteristics of tumor-infiltrating lymphocyte heterogeneity in ccRCC and other malignancies.Competing Interest StatementNo potential conflicts of interest to report: MCF, NC, BIC, YK, JKT, AB, MF, ES, ENK, GB, BJM, PMA. JM has ownership interest in Fulgent Genetics, Inc., Aleta Biotherapeutics, Inc., Cold Genesys, Inc., Myst Pharma, Inc., and Tailored Therapeutics, Inc., and is a consultant/advisory board member for ONCoPEP, Inc., Cold Genesys, Inc., Morphogenesis, Inc., Mersana Therapeutics, Inc., GammaDelta Therapeutics, Ltd., Myst Pharma, Inc., Tailored Therapeutics, Inc., Verseau Therapeutics, Inc., Iovance Biotherapeutics, Inc., Vault Pharma, Inc., Noble Life Sciences Partners, Fulgent Genetics, Inc., UbiVac, LLC, Vycellix, Inc., and Aleta Biotherapeutics, Inc.Funding StatementUnited States Army Medical Research Acquisition Activity Department of Defense (KC180139 to B.J.M). P.M.A. was supported by an American Cancer Society Moffitt IRG award, the Richard O. Jacobson Foundation (Evolutionary Therapy Center of Excellence at Moffitt Cancer Center), and the William G. "Bill" Bankhead Jr and David Coley Cancer Research Program (20B06).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:H. Lee Moffitt Cancer Center Total Cancer Care protocol MCC# 14690; Advarra IRB Pro00014441All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for VDJ epitope recoveries from patient sequencing data (BAM files) is publicly available on Docker at https://hub.docker.com/r/bchobrut/vdj and GitHub at https://github.com/bchobrut/vdj_recovery. Code for calculating patient CDR3 diversity from CDR3 recoveries is publicly available at: https://github.com/mcfefa/OncoDiversity.jl. CDR3complementarity determining region-3GDIgeneralized diversity indexIPinflection pointKMKaplan-Meier survival curveOSoverall survivalRFSrecurrence free survivalTCRT-cell receptorTRAT-cell receptor alphaTRBT-cell receptor betaTRGT-cell receptor gammaTRDT-cell receptor deltaBCRB-cell receptorIGHB-cell immunoglobulin heavy chainIGKB-cell immunoglobulin kappa light chainIGLB-cell immunoglobulin lambda light chain